Industry News
Pharmaceutical Industry News
Fierce Pharma’s Fraiser…
Fierce Pharma’s Fraiser Kansteiner catches up with KPMG’s Chris Young to discuss the latest pharma tariff developments and how Big Pharma and small- to mid-sized drugmakers are responding.
After losing the top spot in March…
After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the drug with the highest level of ad spending.
You’ve heard of Gen Z, but now…
You’ve heard of Gen Z, but now Johnson & Johnson wants you to be aware of “Generation Fine” as it looks to boost understanding around depression treatment.
Cancer treatments with high levels…
Cancer treatments with high levels of physician awareness at launch maintain their advantage over drugs that are yet to gain widespread recognition when they come to market, a ZoomRx analysis found.
GSK is teaming up with “Modern…
GSK is teaming up with “Modern Family” stars Julie Bowen and Ty Burrell to help get out the messaging: “ask to be sure” about the risks of meningococcal disease.
Louisiana Asks Supreme Court to Halt Abortion Pill Access by Mail
The request comes after a federal appeals court temporarily blocked a Food and Drug Administration regulation that has greatly expanded access to the abortion pill mifepristone.
Summit’s PD-1xVEGF study…
Summit's PD-1xVEGF study surprisingly missed its mark at an interim analysis. UCB will pay $2 billion upfront to buy Candid Therapeutics, which has aggregated a group of Chinese assets. J&J eliminated two CD20 CAR-T programs
With an eye on the lucrative U.S….
With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster Firdapse for $4.1 billion.
After a surprise rejection in…
After a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same single-arm trial that the agency had previously found problematic. The case could reignite investors’ hope of
The FDA has hit Alnylam with an…
The FDA has hit Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech of presenting open-label data that create a misleading impression of the drug’s effects.
Insulet has always been a strong…
Insulet has always been a strong leader in the medtech industry when it comes to its marketing game—and the diabetes device maker isn’t looking to rest on its laurels.
Her Self-Experiment with Drug Detox Almost Broke Her
Against expert advice, people are using new and unpredictable synthetic drugs to experiment on themselves in hopes of becoming free of addiction.
Her Self-Experiment with Drug Detox Almost Broke Her
Against expert advice, people are using new and unpredictable synthetic drugs to experiment on themselves in hopes of becoming free of addiction.
Why AI, point-of-care mindset, and…
Why AI, point-of-care mindset, and coordinated engagement are redefining how pharma brands break through.
American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.
A Bristol Myers Squibb plant that makes cancer drugs was the only manufacturer in the U.S. recognized for innovation by the World Economic Forum this year.
American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.
A Bristol Myers Squibb plant that makes cancer drugs was the only manufacturer in the U.S. recognized for innovation by the World Economic Forum this year.
Tofersen, a New Treatment for A.L.S., Reverses Symptoms for Some
The drug is for a small subset of patients. But evidence that breathing and strength can get better for some of them is remarkable for a paralyzing, usually fatal disease.
Tofersen, a New Treatment for A.L.S., Reverses Symptoms for Some
The drug is for a small subset of patients. But evidence that breathing and strength can get better for some of them is remarkable for a paralyzing, usually fatal disease.
The FDA’s Commissioner’s National…
The FDA's Commissioner's National Priority Voucher program has been steeped in controversy since its inception. Now, Sanofi has asked that one of its applications be taken out of the fast-track program, according to Stat.
In a bid to better deploy its…
In a bid to better deploy its boots-on-the-ground resources, the FDA is rolling out a new pilot program, under which the regulator is leveraging “one-day inspectional assessments” to complement its traditional site visits.